BR112021010720A2 - Métodos para tratar ou prevenir gota ou hiperuricemia - Google Patents

Métodos para tratar ou prevenir gota ou hiperuricemia Download PDF

Info

Publication number
BR112021010720A2
BR112021010720A2 BR112021010720-7A BR112021010720A BR112021010720A2 BR 112021010720 A2 BR112021010720 A2 BR 112021010720A2 BR 112021010720 A BR112021010720 A BR 112021010720A BR 112021010720 A2 BR112021010720 A2 BR 112021010720A2
Authority
BR
Brazil
Prior art keywords
effective amount
therapeutically effective
compound
pharmaceutical composition
individual
Prior art date
Application number
BR112021010720-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Shunqi Yan
Litain Yeh
Rongzi Yan
Original Assignee
Arthrosi Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arthrosi Therapeutics, Inc. filed Critical Arthrosi Therapeutics, Inc.
Publication of BR112021010720A2 publication Critical patent/BR112021010720A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
BR112021010720-7A 2018-12-06 2019-12-05 Métodos para tratar ou prevenir gota ou hiperuricemia BR112021010720A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862776251P 2018-12-06 2018-12-06
US62/776,251 2018-12-06
PCT/US2019/064785 WO2020118114A1 (en) 2018-12-06 2019-12-05 Methods for treating or preventing gout or hyperuricemia

Publications (1)

Publication Number Publication Date
BR112021010720A2 true BR112021010720A2 (pt) 2021-08-31

Family

ID=70974386

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021010720-7A BR112021010720A2 (pt) 2018-12-06 2019-12-05 Métodos para tratar ou prevenir gota ou hiperuricemia

Country Status (12)

Country Link
US (1) US12419854B2 (https=)
EP (1) EP3890722A4 (https=)
JP (1) JP7528080B2 (https=)
CN (1) CN113164439A (https=)
AU (1) AU2019392750B2 (https=)
BR (1) BR112021010720A2 (https=)
CA (1) CA3121624A1 (https=)
EA (1) EA202191543A1 (https=)
IL (1) IL283665A (https=)
SG (1) SG11202105743RA (https=)
TW (1) TW202038936A (https=)
WO (1) WO2020118114A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113214198B (zh) 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN113368032A (zh) * 2020-07-23 2021-09-10 太阳升(亳州)生物医药科技有限公司 药物组合物、口服固体制剂及其制备方法和用途
US20250066316A1 (en) * 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) * 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
HU227530B1 (en) 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
JP2616252B2 (ja) 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
DE19624292A1 (de) 1996-06-18 1998-01-02 Merckle Gmbh Verfahren und Zwischenprodukte zur Herstellung von 1'-Hydroxybenzbromaron
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
EP1767531A4 (en) 2004-06-10 2011-01-05 Torii Pharmaceutical Co Ltd 6-HYDROXYBENZBROMARONE OR SALTING MEDICAL COMPOSITIONS CONTAINING THEREOF
US20080305169A1 (en) 2006-05-26 2008-12-11 Japan Tobacco Inc. Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
JP5325065B2 (ja) 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
IT1400609B1 (it) * 2010-05-10 2013-06-14 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e metformina e loro uso.
US10005750B2 (en) 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
US20150031768A1 (en) 2011-08-19 2015-01-29 The Trustees Of Princeton University C-halogen bond formation
US9060987B2 (en) 2011-11-04 2015-06-23 Cymabay Therapeutics, Inc. Methods for treating gout flares
US9962362B2 (en) 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
US9708388B2 (en) 2012-04-11 2017-07-18 Hoffmann-La Roche Inc. Antibody light chains
KR20210033067A (ko) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 브루톤 타이로신 키나아제 저해제의 결정 형태
WO2014028668A2 (en) 2012-08-14 2014-02-20 Minerva Biotechnologies Corporation Stem cell enhancing therapeutics
JP2016500367A (ja) 2012-12-05 2016-01-12 デュタリス ゲーエムベーハー デュアルターゲティング
WO2014113407A2 (en) 2013-01-16 2014-07-24 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
JP2016512817A (ja) 2013-03-15 2016-05-09 ヤンセン ファーマシューティカ エヌ.ベー. 高尿酸血症の治療におけるカナグリフロジンとプロベネシドの組合せ
CN105579037A (zh) 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
WO2015134467A1 (en) 2014-03-05 2015-09-11 The Trustees Of Princeton University Methods and compositions for direct radioactive labeling of bio-active molecules and building blocks
MX2017001103A (es) 2014-07-31 2017-04-27 Merck Patent Gmbh Derivados de indolizina que son aplicables a enfermedades neurodegenerativas.
CN104262305B (zh) 2014-09-16 2016-06-08 东北制药集团股份有限公司 一种苯溴马隆晶型a及其制备方法
CN104311516B (zh) 2014-09-16 2017-01-11 东北制药集团股份有限公司 一种苯溴马隆晶型b及其制备方法
CN113214198B (zh) 2016-07-18 2022-12-23 广州瑞安博医药科技有限公司 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法
WO2018090921A1 (zh) 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018110887A1 (ko) 2016-12-14 2018-06-21 주식회사 엘지화학 헤테로 고리 화합물 및 이를 포함하는 유기 발광 소자
WO2019195118A1 (en) 2018-04-03 2019-10-10 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
US20210338648A1 (en) 2018-10-01 2021-11-04 Astrazeneca Ab Methods and compositions for reducing serum uric acid
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
US12145917B2 (en) 2018-12-06 2024-11-19 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
EP3968989A4 (en) 2019-05-14 2022-12-28 Arthrosi Therapeutics, Inc. COMPOUND FOR TREATMENT OF GOUT OR HYPERURICEMIA
CN112952564B (zh) 2019-12-25 2022-04-22 华为数字能源技术有限公司 配电模块及通信电源系统
WO2021252630A1 (en) 2020-06-10 2021-12-16 Arthrosi Therapeutics, Inc. Methods for treating or preventing chronic kidney disease
CN112729156A (zh) 2020-12-24 2021-04-30 上海智能制造功能平台有限公司 一种人体数字化测量装置的数据拼接及系统标定方法
CN114697265A (zh) 2020-12-29 2022-07-01 华为技术服务有限公司 一种报文处理方法及装置
US20250066316A1 (en) 2021-12-02 2025-02-27 Arthrosi Therapeutics, Inc. Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN118974028A (zh) 2021-12-30 2024-11-15 广州瑞安博医药科技有限公司 用于治疗痛风或高尿酸血症的化合物的制备

Also Published As

Publication number Publication date
US20220023251A1 (en) 2022-01-27
EP3890722A4 (en) 2022-08-24
CA3121624A1 (en) 2020-06-11
CN113164439A (zh) 2021-07-23
EP3890722A1 (en) 2021-10-13
AU2019392750B2 (en) 2025-07-10
EA202191543A1 (ru) 2021-10-26
KR20210102933A (ko) 2021-08-20
AU2019392750A1 (en) 2021-07-15
JP2022510303A (ja) 2022-01-26
IL283665A (en) 2021-07-29
SG11202105743RA (en) 2021-06-29
US12419854B2 (en) 2025-09-23
WO2020118114A1 (en) 2020-06-11
TW202038936A (zh) 2020-11-01
JP7528080B2 (ja) 2024-08-05

Similar Documents

Publication Publication Date Title
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
US12419854B2 (en) Methods for treating or preventing gout or hyperuricemia
US20250059150A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
US20250066316A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
US12612401B2 (en) Crystalline forms of an S1P receptor modulator
KR102956127B1 (ko) 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
EA049585B1 (ru) Соединение для лечения подагры или гиперурикемии
HK40060723A (en) Compound for treating gout or hyperuricemia

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]